Stay updated with breaking news from Therapy Evaluation Program. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- Announced positive results from the pivotal Phase 3 SIERRA trial of Iomab-B in r/r AML patients ages 55+; achieved primary endpoint of dCR with high...
Drs. Roger B. Cohen, Lee M. Ellis and John L. Marshall Join Actuate Therapeutics’ Scientific Advisory Board - read this article along with other careers information, tips and advice on BioSpace
For results from clinical trials to be more generalizable, there needs to be some loosening of exclusion criteria, say researchers who report that some headway has been made.
The proportion of AYAs enrolled in clinical trials increased after the launch of the National Clinical Trials Network in 2014.
The proportion of adolescents and young adults (AYAs; aged 15 to 39 years) enrolled in clinical trials increased after launch of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN) in 2014.